Programmed Death Receptor-1 Blocking Antibody class drugs
3 results
Jemperli (dostarlimab)
(dostarlimab)GlaxoSmithKline LLC
Usage: JEMPERLI is indicated for adult patients with primary advanced or recurrent endometrial cancer, in combination with carboplatin and paclitaxel, or as a single agent for mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed after prior treatment and lack satisfactory alternatives.
Loqtorzi (toripalimab-tpzi)
(toripalimab-tpzi)Coherus BioSciences, Inc.
Usage: LOQTORZI is indicated for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine. It is also indicated as a single agent for adults with recurrent unresectable or metastatic NPC after progression on platinum-based chemotherapy.
Opdualag (nivolumab and relatlimab-rmbw)
(nivolumab and relatlimab-rmbw)E.R. Squibb & Sons, L.L.C.
Usage: OPDUALAG™ is indicated for treating adult and pediatric patients aged 12 and older with unresectable or metastatic melanoma.